Joined in 2023 
82 
63 About this deal
MEBO ointment may change its physical appearance during storage. especially during hot seasons. but it does not loose its efficacy. MEBO Ointment Presentation :
S18 TI ( topical N3 steroid* or topical N3 corticosteroid* or topical N3 glucocorticoid* ) or AB ( topical N3 steroid* or topical N3 corticosteroid* or topical N3 glucocorticoid* )
A sterile gauze should be impregnated with MEBO and should fill the cavity of the ulcer, and renewed twice daily. Wound exudate: the material composed of serum, fibrin, and white blood cells that oozes from a skin wound The high risk of bias was mostly related to a high risk of performance and detection bias due to absent blinding of participants, providers and, to a lesser extent, outcome assessors. Blinding of participants and care providers is not easy in studies that compare topical interventions, but outcome assessors could have been blinded. Despite this possibility, only three out of twelve studies reported blinding of outcome assessors for all outcomes). Selection bias was a second source of bias.
Depending on the seriousness, extension, and location of the damage, applications can be reduced to simple massages to let the ointment be absorbed. Mean time to wound healing: I1: 14.3 (SD 14.5) days; I2: 21.4 (SD 37.6) days (data delivered upon request). There is low‐certainty evidence that a skin substitute may slightly reduce time to partial (i.e. greater than 90%) wound healing, compared with a non‐specified antibacterial agent (MD –6.00 days, 95% CI –8.69 to –3.31; 1 study, 34 participants). aerobic and anaerobic micro-organisms have been reported to cause the infection, including streptococci, staphylococci, Enterobacteriaceae and even fungi; polymicrobial cultures predominate and are the leading cause behind the infection’s rapid multiplication and spread. Seven of 12 studies included 'time to complete wound healing' as an outcome of interest ( Table 5). In addition, two studies reported the number of participants healed at 10 days ( Ang 2000) and 14 days ( Tsoutsos 2009). Five studies used 'change in wound surface area over time,' or 'the proportion of the burn wounds partly healed' as an outcome measure, by assessing the percentage wound healing at 3, 5, 7 and 14 days after treatment ( Jiaao 2011), or the time to 90% or 95% wound healing ( Demling 1999; Demling 2002; Oen 2012; Wang 2015).
Time to complete wound healing, pain, wound infection, scar quality, adverse effects (rash irritation) It is used in the treatment of second-degree burns, which are relatively deeper than first-degree burns
Cultures from the wounds revealed polymicrobial infections with at least two micro-organisms, but no anaerobes were found, even though we cannot rule out their presence, which might have been undetected owing to technical faults. observer report): I1: 1.4 (25–75th percentile 1.2–1.8); I2: 1.4 (25–75th percentile 1.2–1.6), reported P = 0.17. Well‐designed and conducted RCTs are rated as high‐certainty evidence. We downgraded the evidence to moderate, low or very low depending on the presence of each of the following factors:Apply a thin layer of MEBO cream to the affected area 3 to 4 times daily, or as directed by the doctor Precautions and warnings: Three studies compared topical antimicrobial versus non‐antimicrobial agents. These studies included comparisons between SSD and the non‐antimicrobial Moist Exposed Burn Ointment (MEBO) ( Ang 2000), and between a topical antimicrobial hydrocolloid dressing (Aquacel Ag) and MEBO ( Hindy 2009; Mabrouk 2012). Four additional potentially eligible studies were excluded in this update. Full‐text analysis resulted in four exclusions because the study was not an RCT ( Schulz 2016), or did not involve facial burns ( Aboelnaga 2018; Hundeshagen 2018; Moenadjat 2008). Wound infection (as defined by the trial authors). We did not include data on wound colonisation unrelated to infection. Topical agents included antimicrobial agents (silver sulphadiazine (SSD), Aquacel‐Ag, cerium‐sulphadiazine, gentamicin cream, mafenide acetate cream, bacitracin), non‐antimicrobial agents (Moist Exposed Burn Ointment (MEBO), saline‐soaked dressings, skin substitutes (including bioengineered skin substitute (TransCyte), allograft, and xenograft (porcine Xenoderm), and miscellaneous treatments (growth hormone therapy, recombinant human granulocyte‐macrophage colony‐stimulating factor hydrogel (rhGMCS)), enzymatic debridement, and cream with Helix Aspersa extract).
Cream containing Helix Aspersa extract (terrestrial brown snail secretions extract (Elicina) vs MEBO Two review authors (CH and MvB) made systematic and independent assessments of the risk of bias of each trial, using the Cochrane 'Risk of bias' criteria ( Higgins 2017). To provide independent assessment of risk of bias, a third person (Inge Spronk) not involved in one included study and CH performed data extraction and risk of bias assessment of the study from Oen 2012. A member of Cochrane Wounds (Zhenmi Liu) assessed a paper in the Chinese language. The criteria related to the following issues:A thin tayer of MEBO should be applied to the nipple under a light pad. and renewed 3 . 4 times daily. MEBO is safe for the infant that nursing can proceed Without any hazards. Studies were considered for inclusion if topical therapy was applied and compared with any comparator intervention. We defined topical therapy as any remedy, agent, substance, device or skin substitute (biological or bioengineered) that was applied to the surface of the facial wound in the acute phase with the aim of treating the burn. We defined the acute phase as the period of wound healing that occurred up to wound closure (epithelialisation). We divided the topical interventions considered for inclusion into the following five categories: MEBO: Moist Exposed Burn Ointment; rhGM‐CSF: recombinant human granulocyte‐macrophage colony‐stimulating factor; SSD: silver sulphadiazine. S7 TI ( face or facial or nose or mouth or ear or ears) or AB ( face or facial or nose or mouth or ear or ears ) MEBO is of natural and herbal edible O(lgln, It IS composed of B·sitosterol 0.25% as the main active ingredient. The base of the Ointment IS composed of sesame oil and beeswax. tn addition to that, MEBO includes In Its formula 18 amino acids. 4 major fatty acids, vitamins. and polysaccharides. MEBO Ointment Mode of Action :
Great Deal 
New Comment